APEIRON Biologics GmbH – Trademark Portfolio
Entity Type: 98
APEIRON Biologics GmbH holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ACELLT and T ACELLT APEIRON CELL THERAPIES.
Campus-Vienna-Biocenter 5
A-1030 Wien
Showing of trademarks Trademarks
Trademark Classifications
APEIRON Biologics GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does APEIRON Biologics GmbH have?
APEIRON Biologics GmbH has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does APEIRON Biologics GmbH file in?
APEIRON Biologics GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are APEIRON Biologics GmbH's most well-known trademarks?
APEIRON Biologics GmbH's registered trademark portfolio includes well-known marks such as ACELLT and T ACELLT APEIRON CELL THERAPIES. These are among 2 currently registered trademarks in the portfolio.
What is APEIRON Biologics GmbH's trademark registration success rate?
APEIRON Biologics GmbH has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.